Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.91 -0.09 (-0.06%) Market Cap: 14.28 Bil Enterprise Value: 13.58 Bil PE Ratio: 39.09 PB Ratio: 5.98 GF Score: 89/100

Neurocrine Biosciences Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 02:10PM GMT
Release Date Price: $87.98 (+0.03%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning, and welcome once again to Cowen & Company's 42nd Annual Healthcare Conference. I'm Phil Nadeau, I'm a biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with CEO of Neurocrine, Kevin Gorman. Those of you who follow our research know that we are fans of Neurocrine as we think there is much growth left in INGREZZA and an undiscovered pipeline.

Kevin, maybe I'll hand it to you to give a brief state of the company overview, biggest trends, biggest challenges and what you think needs to happen for Neurocrine to drive outperformance over the next couple of years.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thanks, Phil. Good to see you. I'm here in a hotel room in your [fair] city of Boston. So bear with me, I'm trying to make sure that at least the audio is going to stay very stable in here, the video may click around a little bit. So kind of working off of 2 devices here. And I will start out with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot